{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:21:32Z","timestamp":1791591692236,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.urolonc.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T16:10:34Z","timestamp":1593965434000},"page":"737.e11-737.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy"],"prefix":"10.1016","volume":"38","author":[{"given":"Yuval","family":"Freifeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid M.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magomet","family":"Gazimiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Delafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Kulangara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Robyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas G.","family":"Petros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.05.002_bib0001","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1464-410X.2005.05804.x","article-title":"Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology","volume":"96","author":"Raman","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/iju.12121","article-title":"Bladder recurrence after radical nephroureterectomy: Predictors and impact on oncological outcomes","volume":"20","author":"Elalouf","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14737140.2018.1481395","article-title":"Therapeutic strategies for upper tract urothelial carcinoma","volume":"18","author":"Freifeld","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0004","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0005","first-page":"3821","article-title":"Clipping the extremity of ureter prior to nephroureterectomy is effective in preventing subsequent bladder recurrence after upper urinary tract urothelial carcinoma","volume":"125","author":"Chen","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0006","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyx085","article-title":"Efficacy of early ureteral ligation on prevention of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: a prospective single-arm multicenter clinical trial","volume":"47","author":"Ito","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0007","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","article-title":"Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial)","volume":"60","author":"O'Brien","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0008","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.urolonc.2016.10.016","article-title":"Intravesical chemotherapy use after radical nephroureterectomy: a national survey of urologic oncologists","volume":"35","author":"Lu","year":"2017","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12894-015-0039-0","article-title":"Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy","volume":"15","author":"Moriarty","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/BLC-180174","article-title":"Evaluation of intraoperative versus postoperative adjuvant mitomycin C with nephroureterectomy for urothelial carcinoma of the upper urinary tract","volume":"4","author":"Noennig","year":"2018","journal-title":"Bladder Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0012","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","article-title":"Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urolonc.2009.06.003","article-title":"Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance","volume":"29","author":"Az\u00e9mar","year":"2011","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0014","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0022-5347(17)44926-3","article-title":"The mechanism of human bladder tumor implantation in an in vitro model","volume":"136","author":"Pode","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0015","first-page":"1229","article-title":"Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and metaanalysis","volume":"20","author":"Wu","year":"2015","journal-title":"J BUON"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0018","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.05.002_bib0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00345-019-02768-w","article-title":"Diagnostic ureteroscopy prior to nephroureterectomy for urothelial carcinoma is associated with a high risk of bladder recurrence despite technical precautions to avoid tumor spillage","volume":"38","author":"Baboudjian","year":"2020","journal-title":"World J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:13Z","timestamp":1761041953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920301964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1078143920301964"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}